Efficacy and Tolerability of Extended-release Oxybutynin in Children with a Neurogenic Bladder.
10.4111/kju.2007.48.10.1064
- Author:
Jin Mo UM
1
;
Kwang Myung KIM
Author Information
1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. kwang@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Oxybutynin;
Children;
Neurogenic bladder
- MeSH:
Body Weight;
Child*;
Cholinergic Antagonists;
Compliance;
Humans;
Interviews as Topic;
Medical Records;
Meningomyelocele;
Urinary Bladder, Neurogenic*
- From:Korean Journal of Urology
2007;48(10):1064-1068
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The aim of this study was to investigate the efficacy and tolerability of extended-release oxybutynin(oxybutynin ER) in children with a neurogenic bladder. MATERIALS AND METHODS: Fifty-four patients(21 myelomeningocele and 33 lipomyelomeningocele) with a neurogenic bladder were enrolled in the study. We reviewed the medical records and performed a telephone interview. The treatments were changed from immediate-release oxybutynin (oxybutynin IR) or other anticholinergics to oxybutynin ER from August to December 2006. The mean age of the study patients was 11.1 years (range 4 to 18 years) and the mean body weight was 37.9kg(range 16.2 to 72.0kg). All patients were asked about the effectiveness, side effects and compliance with the medication. The number of voids, volume of urine per void or clean intermittent catheterization(CIC) and number of incontinence episodes were also evaluated. RESULTS: The mean duration of oxybutynin ER treatment was 16.3 weeks (range 7-25 weeks). Twenty-six patients(48.1%) responded they had improvement in voiding symptoms. Among the patients, there was a significant reduction in the number of incontinence episodes(from 3.3 to 1.3, p<0.001) with the change in medications. The number of voids or CIC per 24 hours and the maximum volume of urine per void or CIC did not show a significant change. Another twenty-eight patients(51.9%) responded that the improvements were maintained. Among these patients, there were no significant changes of the medications. Only five patients (9.3%) changed their medication because of the side effects. CONCLUSIONS: The results of this study showed that the extended-release oxybutynin was effective and well tolerated in children with a neurogenic bladder.
